These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25194722)

  • 1. Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
    Nasr DM; Biller J; Rabinstein AA
    Pediatr Neurol; 2014 Nov; 51(5):624-31. PubMed ID: 25194722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
    Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between hospital volume and early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
    Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
    Int J Stroke; 2015 Jan; 10(1):73-8. PubMed ID: 25043743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
    Boddu DB; Srinivasarao Bandaru VC; Reddy PG; Madhusudan M; Rukmini MK; Suryaprabha T; Jabeen SA; Suvarna A; Jayalakshmi SS; Meena AK; Borgohain R; Kaul S
    Neurol India; 2010; 58(3):403-6. PubMed ID: 20644268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of intravenous thrombolysis is increasing in the United States.
    Nasr DM; Brinjikji W; Cloft HJ; Rabinstein AA
    Int J Stroke; 2013 Dec; 8(8):681-8. PubMed ID: 22882725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States trends in thrombolysis for older adults with acute ischemic stroke.
    George BP; Asemota AO; Dorsey ER; Haider AH; Smart BJ; Urrutia VC; Schneider EB
    Clin Neurol Neurosurg; 2015 Dec; 139():16-23. PubMed ID: 26363362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
    Huang YH; Zhuo ST; Chen YF; Li MM; Lin YY; Yang ML; Chen ZJ; Cai RW
    Chin Med J (Engl); 2013; 126(24):4685-90. PubMed ID: 24342312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
    Cremer S; Berliner Y; Warren D; Jones AE
    CJEM; 2008 Nov; 10(6):575-8. PubMed ID: 19000355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis with rt-PA for acute ischemic stroke within 24h of a transient ischemic attack.
    Sobolewski P; Brola W; Wiszniewska M; Szczuchniak W; Fudala M; Domagalski M; Sledzińska-Dźwigał M
    J Neurol Sci; 2014 May; 340(1-2):44-9. PubMed ID: 24635889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry.
    Makihara N; Okada Y; Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Hasegawa Y; Kario K; Okuda S; Naganuma M; Toyoda K
    Cerebrovasc Dis; 2012; 33(3):240-7. PubMed ID: 22261711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
    Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
    JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of acute kidney injury on in-hospital mortality in acute ischemic stroke patients undergoing intravenous thrombolysis.
    Gadalean F; Simu M; Parv F; Vorovenci R; Tudor R; Schiller A; Timar R; Petrica L; Velciov S; Gluhovschi C; Bob F; Mihaescu A; Timar B; Spasovski G; Ivan V
    PLoS One; 2017; 12(10):e0185589. PubMed ID: 29040276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.